Abstract:As the medicalization of marijuana occurs across the United States, the main non‐psychoactive component of the marijuana, cannabidiol (CBD), has gained recognition. Given that anxiety is the most common type of mental illness in the United States, our objective was to access the therapeutic potential of CBD administration. We hypothesized that CBD could mitigate anxiety for chronic but not acute treatments in mice and would not have long‐term behavioral consequences when administered perinatally. Our methods employed 3‐mo. Kv1.3‐/‐ (KO) anxiety prone mice, or wildtype (WT) mice that were treated either acutely (daily for 1 wk), chronically (18 doses over 1 mo.), or throughout gestation and lactation (daily). Mice in the acute and chronic treatment groups were randomly assigned to intraperitoneal injection of drug (CBD = 10 or 20 mg/kg) or vehicle solution. CBD administered to dams was provided orally via strawberry jam (100 mg/kg). The effect of perinatal exposure to CBD was assessed at 3 mo. of age. Mice were behaviorally assessed using five tasks: the elevated plus maze (EPM), the light‐dark box (LDB), the marble burying test, a 1‐ and 24‐hour memory test, and an object attention test for ADHD. Mice treated acutely with the drug exhibited decreased obsessive compulsive behavior (buried less marbles) in only male mice, and the required dose to produce this behavior was higher for KO mice. In the LDB test, CBD lessened anxiety for both sexes, yet WT females required a lower CBD dose than WT male mice; in KO mice, CBD was anxiogenic rather than anxiolytic for both sexes. When mice were challenged with the EPM, mice spent more time in the closed arms regardless of sex, genotype, or drug treatment. The only exception was CBD treated female KO mice exhibited anxiety in the EPM, spending more time in the closed arms following drug treatment. Although acute CBD decreased obsessive compulsive behavior, when administered chronically the drug had no effect in either WT or KO mice. Similar to acute CBD administration in WT mice, chronic drug administration lessened anxiety in the LDB (increased time in the light compartment). However, in KO mice, chronic administration of CBD was without effect in the LDB. For mice treated perinatally, there was no significant drug effect for litter size (p = 0.3619), time to birth (p = 0.4210), or maternal weight gain (p = 0.1588). CBD‐treated offspring had a lower survival rate in that 48.5% of CBD‐treated pups died before weaning age (23 days) whereas only 5.7% of jam treated pups died prior to weaning (p = 0.0355). In conclusion, our data suggest that CBD may act as an anxiolytic drug in WT mice with dose and sex dependency. CBD failed to alleviate anxiety in KO mice, suggesting that CBD may not be affective in subjects that already have trait anxiety rather than situation anxiety. CBD had no effect on object memory or ADHD‐like behaviors regardless of dose, duration, or genotype.

Gestational CBD shapes insular cortex in adulthood

Gestational CBD Shapes Insular Cortex in Adulthood

Sex-specific disruptions in the developmental trajectory of anxiety due to prenatal cannabidiol exposure

Cannabinoid Receptor 1 Signaling in Embryo Neurodevelopment

CB1 and CB2 receptors differentially modulate the cognitive impact of maternal immune activation and perinatal cannabinoid exposure

Oral cannabidiol administration in mice during pregnancy and lactation affects early postnatal body weight, fasting glucose, ingestive behavior, anxiety- and obsessive compulsive-like behaviors, and long-term object-memory in adult offspring in a sex-dependent manner

Cannabidiol Exposure During Gestation Leads to Adverse Cardiac Outcomes Early in Postnatal Life in Male Rat Offspring

CBD enhances the cognitive score of adolescent rats prenatally exposed to THC and fine-tunes relevant effectors of hippocampal plasticity

Prenatal tetrahydrocannabinol and cannabidiol exposure produce sex-specific pathophysiological phenotypes in the adolescent prefrontal cortex and hippocampus

Long-term effects on cardiorespiratory and behavioral responses in male and female rats prenatally exposed to cannabinoid

Cannabidiol Exposure During Rat Pregnancy Leads to Labyrinth-Specific Vascular Defects in the Placenta and Reduced Fetal Growth

Maternal immune activation alters social affective behavior and sensitivity to corticotropin releasing factor in male but not female rats

Impact of prenatal delta-9-tetrahydrocannabinol exposure on mouse brain development: a fetal-to-adulthood magnetic resonance imaging study

Acute, Chronic, and Prenatal Exposure to Cannabidiol (CBD) Differentially Affects Anxiety and Successful Birthrate in Mice

Maternal Immune Activation Alters Fetal Brain Development and Enhances Proliferation of Neural Precursor Cells in Rats

Life-long epigenetic programming of cortical architecture by maternal ‘Western’ diet during pregnancy

Prenatal Cannabinoid Exposure Elicits Memory Deficits Associated with Reduced PSA-NCAM Expression, Altered Glutamatergic Signaling, and Adaptations in Hippocampal Synaptic Plasticity

Maternal cannabis use alters excitatory inputs to corticostriatal efferent neurons in rat offspring

Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model

Maternal treatment with a selective delta-opioid receptor agonist during gestation has a sex-specific pro-cognitive action in offspring: mechanisms involved

Prenatal Disruption of Blood-Brain Barrier Formation Via Cyclooxygenase Activation Leads to Lifelong Brain Inflammation